Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Efficient and irreversible antibody-cysteine bioconjugation using carbonylacrylic reagents

Full text
Bernardim, Barbara [1, 2] ; Matos, Maria J. [2] ; Ferhati, Xhenti [3] ; Companon, Ismael [3] ; Guerreiro, Ana [4] ; Akkapeddi, Padma [4] ; Burtoloso, Antonio C. B. [5] ; Jimenez-Oses, Gonzalo [3] ; Corzana, Francisco [3] ; Bernardes, Goncalo J. L. [4, 2]
Total Authors: 10
[1] Univ Fed Sao Carlos, Dept Quim, Sao Carlos, SP - Brazil
[2] Univ Cambridge, Dept Chem, Cambridge - England
[3] Univ La Rioja, Dept Quim, Ctr Invest Sintesis Quim, Logrono - Spain
[4] Univ Lisbon, Inst Med Mol, Fac Med, Lisbon - Portugal
[5] Univ Sao Paulo, Inst Quim Sao Carlos, Sao Carlos, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Nature Protocols; v. 14, n. 1, p. 86-99, JAN 2019.
Web of Science Citations: 2

There is considerable interest in the development of chemical methods for the precise, site-selective modification of antibodies for therapeutic applications. In this protocol, we describe a strategy for the irreversible and selective modification of cysteine residues on antibodies, using functionalized carbonylacrylic reagents. This protocol is based on a thiol-Michael-type addition of native or engineered cysteine residues to carbonylacrylic reagents equipped with functional compounds such as cytotoxic drugs. This approach is a robust alternative to the conventional maleimide technique; the reaction is irreversible and uses synthetically accessible reagents. Complete conversion to the conjugates, with improved quality and homogeneity, is often achieved using a minimal excess (typically between 5 and 10 equiv.) of the carbonylacrylic reagent. Potential applications of this method cover a broad scope of cysteine-tagged antibodies in various formats (full-length IgGs, nanobodies) for the site-selective incorporation of cytotoxic drugs without loss of antigen-binding affinity. Both the synthesis of the carbonylacrylic reagent armed with a synthetic molecule of interest and the subsequent preparation of the chemically defined, homogeneous antibody conjugate can be achieved within 48 h and can be easily performed by nonspecialists. Importantly, the conjugates formed are stable in human plasma. The use of liquid chromatography-mass spectrometry (LC-MS) analysis is recommended for monitoring the progression of the bioconjugation reactions on protein and antibody substrates with accurate resolution. (AU)

FAPESP's process: 13/25504-1 - Development of new methodologies for the asymmetric a-functionalization of carbonyl compounds using chiral catalysts
Grantee:Antonio Carlos Bender Burtoloso
Support type: Regular Research Grants
FAPESP's process: 15/07509-1 - Site-specific modification of proteins via aqueous Horner-Wadsworth-Emmons reaction followed by Wolff rearrangement
Grantee:Barbara Bernardim de Souza
Support type: Scholarships abroad - Research Internship - Doctorate
FAPESP's process: 17/13168-8 - Construction of chemically defined antibody-drug conjugates using carbonylacrylic reagents
Grantee:Barbara Bernardim de Souza
Support type: Scholarships abroad - Research Internship - Post-doctor